Tirzepatide vs Semaglutide: Which Weight Loss Medication Should You Choose?

7 min read · Published March 24, 2026 · Reviewed by Dr. [Physician Name]

If you are considering GLP-1 treatment for weight management in the Philippines, you are almost certainly weighing two options: tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy).

Both are effective. Both are injectable. Both require a prescription. But they are not interchangeable, and the clinical differences are now well-documented — including the first direct head-to-head trial published in 2025.

The Mechanism: One Receptor vs Two

Semaglutide activates the GLP-1 receptor. This single-pathway approach reduces appetite, slows gastric emptying, and enhances insulin secretion.

Tirzepatide activates both GLP-1 and GIP receptors simultaneously. This dual mechanism provides broader metabolic effects — enhanced insulin sensitivity, improved fat metabolism, and more pronounced appetite suppression.

Weight Loss: The Head-to-Head Data

The SURMOUNT-5 trial (New England Journal of Medicine, 2025) enrolled 751 adults with obesity and randomized them to tirzepatide or semaglutide at maximum tolerated doses for 72 weeks.

Tirzepatide group: 20.2% mean body weight reduction. Semaglutide group: 13.7% mean body weight reduction.

The proportions reaching specific thresholds tell the story clearly: at least 10% weight loss was achieved by 82% of tirzepatide patients vs 61% of semaglutide patients. At least 20% was achieved by 48% vs 27%.

Tirzepatide also produced greater reductions in waist circumference — 18.4 cm versus 13.0 cm.

For a broader understanding of tirzepatide's evidence base, see our complete guide to tirzepatide in the Philippines.

Side Effects: Comparable Profiles

In SURMOUNT-5, side effect profiles were similar between both medications. The most common adverse events were gastrointestinal — nausea, diarrhea, constipation — mostly during dose escalation. Discontinuation rates due to side effects were comparable.

Both carry the same class-level warnings: pancreatitis risk, gallbladder complications, and thyroid C-cell tumors (observed in animal studies). Both are contraindicated with a history of medullary thyroid carcinoma or MEN 2.

For a thorough review of the safety data, see our dedicated guide to tirzepatide side effects.

Cost and Availability in the Philippines

Semaglutide has been available longer locally, is stocked at more pharmacies, and compounded options are generally less expensive.

Tirzepatide availability has improved in 2025-2026. Compounded options are offered by a growing number of providers. It remains somewhat more expensive but the gap is narrowing.

Approximate ranges: compounded semaglutide programs ₱5,000–₱12,000 per month. Compounded tirzepatide programs ₱7,000–₱15,000 per month. Branded products are significantly more for both.

How to Decide

Tirzepatide may be preferred when the clinical goal requires maximum weight reduction, the patient has metabolic comorbidities that benefit from the dual mechanism, or the patient has used semaglutide without achieving sufficient results.

Semaglutide may be preferred when cost is a primary constraint, the patient prefers a medication with a longer market track record, or the physician recommends it based on the patient's specific health history.

Both are legitimate, evidence-based options. The choice depends on your medical profile, goals, and physician's clinical judgment.

For a practical walkthrough of the access process, see how to get tirzepatide in the Philippines.

This article is for educational purposes only and does not constitute medical advice. All treatments require evaluation and prescription by a licensed physician. Individual results vary. Kora Health does not guarantee specific outcomes.